- Home
- CCEC vs COLL Comparison
CCEC vs COLL Comparison
Compare CCEC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | COLL |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CCEC | COLL |
|---|---|---|
| Price | $20.72 | $49.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $26.00 | ★ $47.50 |
| AVG Volume (30 Days) | 13.6K | ★ 515.8K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 304.00 | N/A |
| EPS | ★ 4.79 | 1.63 |
| Revenue | $421,795,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $14.60 | $26.35 |
| Revenue Next Year | $14.43 | $3.67 |
| P/E Ratio | ★ $8.18 | $29.92 |
| Revenue Growth | ★ 32.74 | 26.34 |
| 52 Week Low | $14.09 | $23.23 |
| 52 Week High | $24.83 | $49.16 |
Technical Indicators
Market Signals| Indicator | CCEC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 71.79 |
| Support Level | $20.11 | $47.86 |
| Resistance Level | $21.03 | $49.16 |
| Average True Range (ATR) | 0.79 | 1.33 |
| MACD | 0.13 | -0.15 |
| Stochastic Oscillator | 73.33 | 92.01 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.